Search

AF solution

Chevron
Gastric Cancer Organoid_main
Cancer Organoid

Gastric Cancer Organoid

Gastric Cancer Organoid_main

  • Patient-Specific Tumor Replication
    ▶ Our gastric cancer organoids replicate patient-specific tumors by expressing key markers, enabling personalized treatment research.
  • Advanced Disease Modeling
    ▶ These organoids offer detailed models for studying tumor behavior and responses to treatments, reflecting actual patient conditions.
  • Enhanced Drug Screening Efficiency
    ▶ Using these organoids in drug testing streamlines the process, quickly identifies effective treatments, and reduces research costs and duration

Organism
Product Type
Tissue
Disease
Gastric Cancer

Applications

Drug Test (Organoid Only)

Establishing a process for isolating cytotoxic T cells that can directly attack cancer cells, creating an MHC-TCR
interaction environment, and utilizing MHC I/II blockers to achieve an immune microenvironment in vivo.

Using Immune Cell Co-culture

Establishing a process for isolating cytotoxic T cells that can directly attack cancer cells, creating an MHC-TCR
interaction environment, and utilizing MHC I/II blockers to achieve an immune microenvironment in vivo.

Using Cancer Associate Fibroblast

Establishing a process for isolating cytotoxic T cells that can directly attack cancer cells, creating an MHC-TCR
interaction environment, and utilizing MHC I/II blockers to achieve an immune microenvironment in vivo.

Table of Contents

Innovative gastric modeling with hGC organoids

Delve into the complexities of gastric cancer with our human gastric cancer(hGC) Organoids, engineered through pioneering 3D culture techniques to mirror the intricate ecosystem of human stomach tissues.
These models excel in reflecting the diverse cellular landscape, offering researchers a profound platform for groundbreaking studies and the development of targeted therapies.

Gastric cancer organoid

Our hGC Organoids are a breakthrough in gastric cancer research, meticulously engineered to replicate the specific tumor environment with the expression of key markers CK7, CEA, and LGR5.
This precise molecular reproduction not only ensures high fidelity in modeling but also deepens our understanding of gastric cancer pathology.
By mirroring the complex biology of patient tumors, our organoids facilitate the development of personalized therapies, opening new avenues for innovative treatment solutions.
Explore the possibilities with our hGC Organoids and lead the way in targeted cancer therapy.

H&E
CK7
CEA
LGR5

Cancer tissue

Cancer organoid

Genetic mutation 

Unlock the essence of precision in cancer treatment with our GC organoids, mirroring the  genetic markers of gastric cancer.
Experience the future of testing you drugs, serving as an invaluable tool in capturing the patient-specific characteristics, thereby providing a more accurate platform for studying tumor biology and testing  Dive into a new era of oncology, where your individuality guides our innovation.

Top mutated genes

Performing WES analysis on 16 gastric cancer (hGC) samples, the top 30 gene mutations were observed to be noticeably present across the samples, indicating a high level of mutation.
According to these results, it appears that conducting experiments using the various types of gastric cancer samples we possess will likely yield results similar to those observed in actual human cases.

Gastric cancer mutation PPI Network

Drug response

Embrace personalized medicine with our cutting-edge platform:
Test your drug’s effectiveness against conventional treatments under optimal conditions and discover tailored therapeutic responses. Transform the standard with us—where your medication’s potential is as unique as you are.

hPC Gemcitabine

hPC Paclitaxel

We have confirmed varying efficacy among patients when treating pancreatic cancer organoids derived from patients with representative chemotherapeutic agents such as gemcitabine and paclitaxel.
This underscores the potential for selecting personalized drugs tailored to each patient.
Furthermore, matching these treatments with patients genetic profiles could significantly aid in selecting appropriate chemotherapy agents. We aim to contribute to the advancement of personalized cancer therapy based on these findings.

Patient-specific drug reactivity

Each patient displays individual variations in drug response patterns, making it possible to explore the optimal medication for each patient.
Explore patient-specific drug reactivity using our state-of-the-art platform.
Assess your medication’s efficacy compared to standard treatments in optimal conditions and uncover customized therapeutic responses.

Patient#1
G12D
Patient#2
G12V
Patient#3
G12D
Patient#4
G12V

Vehicle

Drug X

Dead cell

Nuclear